NeueHealth(NEUE)

Search documents
NeueHealth(NEUE) - 2024 Q4 - Annual Report
2025-03-21 20:04
FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NEUEHEALTH, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4991296 (State or other jurisdiction of incorporation or organization) 9250 NW 36th St Suite 420, Doral, FL 33178 (Address of principal executive offices) (Zip Code) Registrant's telepho ...
NeueHealth(NEUE) - 2024 Q4 - Earnings Call Transcript
2025-03-20 17:14
Financial Data and Key Metrics Changes - In Q4 2024, NeueHealth reported consolidated revenue of $232.6 million, with full-year revenue reaching $936.7 million [15] - The gross margin for Q4 was $47.7 million, while the full-year gross margin was $194.5 million [15] - Adjusted EBITDA for Q4 was $5.5 million, contributing to a total of $22.5 million for the full year, marking the fourth consecutive quarter of adjusted EBITDA profitability [15] Business Line Data and Key Metrics Changes - In the NeueCare segment, Q4 revenue was $79.3 million, with full-year revenue at $313.7 million; operating income for Q4 was $9.2 million and $29.6 million for the full year [16] - The NeueSolutions segment generated $157.1 million in revenue for Q4 and $635.1 million for the full year, with an operating income of $3.1 million for Q4 and an operating loss of $5.3 million for the full year [18] Market Data and Key Metrics Changes - NeueHealth served 483,000 consumers in 2024, reflecting a compound annual growth rate of 123% since 2020; this number increased to 717,000 consumers at the start of 2025, a 31% growth from 2024 [10][11] - The company expanded its consumer base in recently expanded markets by 97% [11] Company Strategy and Development Direction - NeueHealth aims to continue its focus on high-quality, affordable healthcare, diversifying the populations served across product categories [24] - The company plans to deepen its presence in local communities and expand into new geographies, enhancing its care model [24] - There is a commitment to grow alongside payer partners and strengthen relationships with providers to enable high-quality personalized care [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive change in the healthcare industry and create a seamless experience for consumers, providers, and payers [26] - The company anticipates closing a transaction to be acquired by an affiliate of NEA in Q2 2025, which is expected to provide flexibility and resources for continued growth [12][13] Other Important Information - As of December 31, 2024, NeueHealth had $202.8 million in total cash and investments, with $93.2 million in nonregulated cash and short-term investments [20] Q&A Session Summary - No specific questions and answers were provided in the content.
NeueHealth(NEUE) - 2024 Q4 - Earnings Call Transcript
2025-03-20 17:16
NeueHealth (NEUE) Q4 2024 Earnings Call March 20, 2025 01:16 PM ET Company Participants Emily Lombardi - AVP - Enterprise StrategyMike Mikan - President & CEOJay Matushak - Chief Financial Officer Operator Good morning and thank you for joining us for the NUHealth Q4 twenty twenty four Earnings Conference Call. My name is Carly and I'll be coordinating the call today. I'd like to hand over to your host, Emily Lombardi. The floor is yours. Emily Lombardi Good morning, and welcome to NU Health's fourth quarte ...
NeueHealth(NEUE) - 2024 Q4 - Annual Results
2025-03-20 10:47
Consumer Base Growth - In 2024, NeueHealth served 360,000 value-based consumers, an increase from 355,000 in 2023[3] - As of the start of 2025, NeueHealth reported serving 717,000 consumers, marking a 48% increase compared to 2024[5] Financial Performance - Revenue for the fourth quarter of 2024 was $232,638,000, compared to $292,871,000 in the same quarter of 2023, representing a decrease of approximately 20.6%[3] - Total revenue for the year ended December 31, 2024, was $936.657 million, a decrease of 19.3% from $1,160.802 million in 2023[17] - Net income for the fourth quarter of 2024 was $2,523,000, a significant improvement from a net loss of $460,572,000 in the fourth quarter of 2023[3] - Operating loss for the year ended December 31, 2024, was $107.410 million, compared to a loss of $576.996 million in 2023, showing improvement[17] - Net loss attributable to common shareholders for the year ended December 31, 2024, was $186.330 million, a reduction from $1,200.599 million in 2023[17] Revenue Breakdown - Capitated revenue increased to $259.881 million for the year ended December 31, 2024, up 18.3% from $219.774 million in 2023[17] - ACO REACH revenue decreased significantly to $625.339 million in 2024, down 30.3% from $896.504 million in 2023[17] - ACO REACH revenue for Q4 2024 was $154,249,000, down 29.7% from $219,659,000 in Q4 2023[22] - Total segment revenue decreased to $157,072,000 in Q4 2024 from $220,862,000 in Q4 2023, representing a decline of 29%[22] Cost Management - Medical costs for the year ended December 31, 2024, were $742.140 million, a decrease of 25.6% from $996.582 million in 2023[17] - Medical costs for Q4 2024 were $149,926,000, down from $231,095,000 in Q4 2023, a decrease of 35%[22] - Total operating expenses decreased to $153,968,000 in Q4 2024 from $235,494,000 in Q4 2023, a reduction of 34.6%[22] Operational Metrics - Adjusted EBITDA for the fourth quarter of 2024 was $5,482,000, compared to a loss of $10,356,000 in the same quarter of 2023[3] - Adjusted EBITDA for Q4 2024 was $5,482,000, a significant improvement from a loss of $10,356,000 in Q4 2023[26] - Operating income for Q4 2024 was $3,104,000, compared to a loss of $14,632,000 in Q4 2023[22] - The Operating Cost Ratio increased to 31.3% in Q4 2024 from 22.3% in Q4 2023[27] - Adjusted Operating Cost Ratio improved to 18.4% in Q4 2024, up from 11.1% in Q4 2023[27] Strategic Initiatives - The company has established a strong foundation for strategic growth in 2025, focusing on expanding its consumer base in new and existing markets[2] - NeueHealth is pursuing a merger agreement with NH Holdings 2025, Inc., which will make the company a wholly owned subsidiary of Parent[8] - The company aims to enhance its technology and services to support independent providers and medical groups in performance-based arrangements[7] - The company has filed a preliminary proxy statement with the SEC regarding the merger transaction, urging investors to review the relevant documents carefully[9] Cash and Liabilities - Cash and cash equivalents at the end of the period decreased to $185.405 million from $375.280 million at the beginning of the year[19] - Total current liabilities decreased to $710.228 million in 2024, down from $1,391.257 million in 2023[17] - Total assets decreased to $544.383 million in 2024 from $1,225.480 million in 2023[17] - The company reported a net cash used in operating activities of $123.217 million for the year ended December 31, 2024, compared to $2,726.546 million in 2023[19] Transaction Costs - The company incurred $16,122,000 in transaction-related costs in Q4 2024, compared to $4,363,000 in Q4 2023[26]
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into NeueHealth Inc. ("NEUE").
Prnewswire· 2025-02-12 01:05
Core Viewpoint - An investigation has been initiated by Levi & Korsinsky, LLP regarding potential breaches of fiduciary duty by the board of directors of NeueHealth Inc. (NEUE) [1][2] Group 1 - The investigation focuses on whether the NEUE board of directors has violated its fiduciary duties to the company's stockholders [2] - Levi & Korsinsky, LLP is a nationally recognized law firm with expertise in prosecuting securities litigation and has successfully recovered hundreds of millions of dollars for shareholders [3]
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEUE, ESSA, LTRPA on Behalf of Shareholders
Prnewswire· 2025-02-10 18:06
Group 1 - Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sale of NeueHealth, Inc. to an affiliate of New Enterprise Associates for $7.33 per share in cash [1] - ESSA Bancorp, Inc. is being sold to CNB Financial Corporation for 0.8547 shares of CNB common stock for each share of ESSA common stock [2] - Liberty TripAdvisor Holdings, Inc. is being sold to Tripadvisor, Inc. [2] Group 2 - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief on behalf of shareholders [3] - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options [4] - The firm represents investors globally who have been victims of securities fraud and corporate misconduct, recovering millions on behalf of defrauded investors [4]
NeueHealth, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
ACCESSWIRE Newsroom· 2025-01-20 16:45
Core Viewpoint - NeueHealth, Inc. is under investigation for potential violations of securities laws, prompting affected investors to reach out to the Schall Law Firm for assistance [1] Group 1 - The investigation into NeueHealth, Inc. suggests possible misconduct related to securities regulations [1] - Affected investors are encouraged to contact legal representation to explore their options [1]
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into NeueHealth, Inc. For Securities Fraud
ACCESSWIRE Newsroom· 2025-01-17 16:15
Group 1 - The Schall Law Firm is inviting shareholders who have incurred losses to participate in an inquiry regarding NeueHealth, Inc. for potential securities fraud [1] - The inquiry aims to investigate the circumstances surrounding the alleged fraud and its impact on shareholders [1] - Shareholders are encouraged to reach out to the law firm to discuss their losses and the potential for legal action [1] Group 2 - The inquiry reflects growing concerns about corporate governance and transparency within the healthcare sector, particularly regarding NeueHealth, Inc. [1] - This situation may lead to increased scrutiny of similar companies in the industry, as investors seek to protect their interests [1] - The outcome of the inquiry could have implications for investor confidence in healthcare stocks, especially those with similar business models [1]
NeueHealth, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
ACCESSWIRE Newsroom· 2025-01-16 14:30
Core Viewpoint - NeueHealth, Inc. is under investigation for potential violations of securities laws, prompting affected investors to reach out to the Schall Law Firm for assistance [1] Group 1 - The investigation into NeueHealth, Inc. suggests serious concerns regarding its compliance with securities regulations [1] - Investors impacted by the situation are encouraged to contact legal representation to explore their options [1]
NeueHealth, Inc. (NEUE) Q3 2024 Earnings Conference Call Transcript
Seeking Alpha· 2024-11-10 09:37
Core Points - NeueHealth, Inc. is conducting its Q3 2024 earnings conference call on November 7, 2024, at 8:00 AM ET [1][2] - The call is led by President and CEO Mike Mikan and CFO Jay Matushak [2] Financial Reporting - The earnings call will reference non-GAAP amounts and measures, with reconciliations available in the company's earnings release [4] - Information presented during the call is based on the earnings release issued in Form 8-K dated November 7, 2024 [5]